Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors
Language English Country United States Media print-electronic
Document type Clinical Trial, Journal Article
PubMed
17764453
DOI
10.1111/j.1525-1438.2007.01015.x
PII: IJG1015
Knihovny.cz E-resources
- MeSH
- Algorithms MeSH
- Biopsy methods MeSH
- Surgery, Computer-Assisted methods MeSH
- Adult MeSH
- Ultrasonography, Interventional adverse effects methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Minimally Invasive Surgical Procedures adverse effects methods MeSH
- Abdominal Neoplasms diagnosis pathology surgery MeSH
- Pelvic Neoplasms diagnosis pathology surgery MeSH
- Postoperative Complications surgery MeSH
- Disease Progression MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Feasibility Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
The goal of this study was to evaluate the accuracy and safety of ultrasound-guided tru-cut biopsy in patients with either primarily inoperable pelvic tumor, advanced tumor and compromised performance status, or recurrent pelvic tumor. Altogether, 90 patients were enrolled and only 4 were not suitable for tru-cut biopsy. The biopsy was taken either from pelvic tumor (54.6%), peritoneal visceral or parietal metastases (31.4%), or omental cake (14%). Samples were obtained transvaginally (53.5%) or transabdominally (46.5%). A diagnosis consistent with primary ovarian malignancy was made in 62.8%, metastatic ovarian involvement was found in 10.5%, and extraovarian tumor in 26.7%. The obtained tissue was adequate for histologic diagnosis in 80 out of 86 cases. In four cases, repeated biopsy was required to obtain a sufficient tissue sample. False-negative samples without tumor tissue were obtained in two cases, and those patients were referred for either laparoscopy or minilaparotomy. The diagnostic accuracy of ultrasound-guided tru-cut biopsy reached 97.7% (95% CI 91.85-99.72%). There was only one complication, a bleeding from tumor in a patient with mild thrombocytopenia, requiring laparotomy. In conclusion, ultrasound-guided tru-cut biopsy is safe, reliable, and cost-effective diagnostic method. It can be performed in an outpatient setting without the need for general anesthesia and provides an adequate specimen for histologic analysis, including immunohistochemical methods. It should, therefore, be considered as a method of choice for histologic verification of both advanced primary and recurrent abdomino-pelvic tumors.
References provided by Crossref.org
ISUOG/ESGO Consensus Statement on ultrasound-guided biopsy in gynecological oncology
The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)
Primary retroperitoneal nodal endometrioid carcinoma associated with Lynch syndrome: A case report
Yolk Sac Tumor of the Omentum: A Case Report and Literature Review
Ultrasound in gynecological cancer: is it time for re-evaluation of its uses?